- Home
- GBIO vs BCAB Comparison
GBIO vs BCAB Comparison
Compare GBIO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- BCAB
- Stock Information
- Founded
- GBIO 2016
- BCAB 2007
- Country
- GBIO United States
- BCAB United States
- Employees
- GBIO 115
- BCAB N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- GBIO Health Care
- BCAB Health Care
- Exchange
- GBIO Nasdaq
- BCAB Nasdaq
- Market Cap
- GBIO 29.2M
- BCAB 27.0M
- IPO Year
- GBIO 2020
- BCAB 2020
- Fundamental
- Price
- GBIO $0.36
- BCAB $0.43
- Analyst Decision
- GBIO Strong Buy
- BCAB Buy
- Analyst Count
- GBIO 4
- BCAB 2
- Target Price
- GBIO $7.33
- BCAB $1.00
- AVG Volume (30 Days)
- GBIO 493.7K
- BCAB 538.7K
- Earning Date
- GBIO 05-07-2025
- BCAB 05-06-2025
- Dividend Yield
- GBIO N/A
- BCAB N/A
- EPS Growth
- GBIO N/A
- BCAB N/A
- EPS
- GBIO N/A
- BCAB N/A
- Revenue
- GBIO $24,556,000.00
- BCAB $11,000,000.00
- Revenue This Year
- GBIO N/A
- BCAB N/A
- Revenue Next Year
- GBIO $10.90
- BCAB N/A
- P/E Ratio
- GBIO N/A
- BCAB N/A
- Revenue Growth
- GBIO 146.47
- BCAB N/A
- 52 Week Low
- GBIO $0.32
- BCAB $0.24
- 52 Week High
- GBIO $4.34
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- GBIO 39.03
- BCAB 51.43
- Support Level
- GBIO $0.36
- BCAB $0.43
- Resistance Level
- GBIO $0.41
- BCAB $0.58
- Average True Range (ATR)
- GBIO 0.04
- BCAB 0.06
- MACD
- GBIO -0.00
- BCAB 0.00
- Stochastic Oscillator
- GBIO 9.09
- BCAB 45.21
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.